About Us
The Human Immunology Project Consortium (HIPC) program was established in 2010, and renewed in 2015 and in 2022, by the NIAID Division of Allergy, Immunology, and Transplantation as part of the overall NIAID focus on human immunology. Through this program, well-characterized human cohorts are studied using a variety of modern analytic tools, including multiplex transcriptional, cytokine, and proteomic assays; multiparameter phenotyping of leukocyte subsets; assessment of leukocyte functional status; and multiple computational methods.
Through the HIPC program, centralized research resources and a comprehensive, centralized database will be constructed for use by the greater scientific community. The information gained from the HIPC program will provide a comprehensive understanding of the human immune system and its regulation and will reveal novel associations between components of the immune system and other biological systems, identify novel immune mediators and pathways, establish predictors of vaccine safety in different populations, and enable the rapid evaluation of different vaccine formulations and administration regimens in human populations. This knowledge base will also serve as a foundation for the future study of immune-mediated diseases in the human, such as allergy, asthma, transplant rejection, autoimmune diseases, and a variety of inflammatory diseases.
Mission
Goals
- Define profiles/signatures/fingerprints of steady-state and activated human immune system
- Create centralized knowledge base & resources
- Facilitate investigations of human immunity
- Develop novel applications for human disease
Study
- Perturbations of the steady-state by infection
- Vaccination
- Adjuvant administration
Methods
- Define human transcriptome/proteome using bioinformatics
- Multiplex assays
- Multiparameter phenotyping, systems biology
- Mass spectrometry
Citing ImmuneSpace
ImmuneSpace was designed to hold the data generated by the Human Immunology Project Consortium (HIPC) and provide ways to interact with, visualize, and analyze this data across centers and cross-assays. ImmuneSpace encourages the use of its data and tools by the wider scientific community.
- Copyright
HIPC places no restrictions on the use or distribution of the ImmuneSpace data. Data generated by the federal government is in the public domain and may be freely distributed and copied. Additionally, the National Institutes of Health (NIH) recommends that researchers in their funded projects select a Creative Commons-BY license or commit their work to the public domain. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted. HIPC is not in a position to assess the validity of such claims and, therefore, cannot provide comment or unrestricted permission concerning the use, copying, or distribution of the information contained in ImmuneSpace. All persons reproducing, redistributing, or making commercial use of this information are expected to adhere to the terms and conditions asserted by the copyright holder.
Should any rights holder discover unauthorized use of their data by ImmunesSpace, a removal request can be made to support@immunespace.org.
The original work contributed by ImmuneSpace is licensed under a Creative Commons Attribution 4.0 International License . In any subsequent use of this work, please cite the website using the URL: https://immunespace.org/
- Liability
The information presented on the ImmuneSpace website is based on data submitted by the scientific community. ImmuneSpace cannot independently verify the validity, quality, or biological significance of submitted data. Tools and features are provided to facilitate mining and advanced queries, with the aim of assisting identification of observations of interest.